Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.67 |
| ▸ | CES1 | P23141 | 2/20 | 0.67 |
| ▸ | PARP1 | P09874 | 3/20 | 0.54 |
| ▸ | VNN1 | O95497 | 1/20 | 0.49 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.44 |
| ▸ | CHRNG | P07510 | 1/20 | 0.44 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29781365 | 1.00 | CES2 (0.67) | CES2CES1PARP1VNN1PLA2G7 | |
| SCHEMBL28968857 | 0.98 | CES2 (0.64) | CES2CES1PARP1VNN1PLA2G7 | |
| SCHEMBL31188464 | 0.98 | CES2 (0.64) | CES2CES1PARP1VNN1PLA2G7 | |
| Hydrochloric Acid SCHEMBL29689719 | 0.98 | CES2 (0.64) | CES2CES1PARP1VNN1PLA2G7 | |
| Hydrochloric Acid SCHEMBL6831261 | 0.98 | CES2 (0.64) | CES2CES1PARP1VNN1PLA2G7 | |
| Trifluoroacetic Acid SCHEMBL6602960 | 0.88 | CES2 (0.53) | CES2CES1PARP1VNN1PLA2G7 | |
| SCHEMBL5202387 | 0.84 | CES2 (0.78) | CES2CES1VNN1PLA2G7RAB9A | |
| SCHEMBL3078849 | 0.82 | PARP1 (0.50) | CES2CES1PARP1LCKERN1 | |
| SCHEMBL1061714 | 0.82 | LCK (0.53) | CES2CES1PARP1LCKERN1 | |
| SCHEMBL13885080 | 0.82 | AR (0.58) | CES2CES1PARP1LCKERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 422 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4121421-B1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS AG (CH) | 2026-03-11 | — | — | EP | claimed |
| EP-3625215-B1 | FORMIMIDAMIDINE COMPOUNDS USEFUL AGAINST PHYTOPATHOGENIC MICROORGANISMS | PI INDUSTRIES LTD (IN) | 2023-09-13 | — | — | EP | claimed |
| EP-3694502-B1 | NOVEL SUBSTITUTED CYCLOBUTYLBENZENE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-08-02 | — | — | EP | claimed |
| EP-3911645-B1 | 5-MEMBERED HETEROARYL COMPOUNDS CONTAINING A HYDROXAMATE MOIETY AND THEIR USE | UNIV LILLE (FR) | 2022-12-07 | — | — | EP | claimed |
| CN-114914362-A | Preparation method of efficient and stable titanium ore solar cell | 西安电子科技大学 | 2022-08-16 | — | — | CN | claimed |
| CN-110642741-A | Functionalized benzamide derivatives as antiviral agents against HBV infection | 巴鲁克斯布隆伯格研究所 | 2020-01-03 | — | — | CN | claimed |
| CN-104918612-B | Functionalized benzamide derivatives as antiviral agents against HBV infection | 巴鲁克斯布隆伯格研究所 | 2019-10-25 | — | — | CN | claimed |
| CN-106715415-B | 3-amino-1, 5,6, 7-tetrahydro-4H-indol-4-ones | 拜耳制药股份公司 | 2019-06-14 | — | — | CN | claimed |
| US-20190092720-A1 | FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | BARUCH S BLUMBERG INST (US) | 2019-03-28 | — | — | US | claimed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| WO-2002028353-A2 | PHOSPHATE TRANSPORT INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-11 | — | — | WO | claimed |
| WO-2002020483-A1 | PIPERIDINE DERIVATIVES FOR USE 2,3-OXIDOSQUALENE-LANOSTEROL CYCLASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-14 | — | — | WO | claimed |
| WO-2002012442-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABAA RECEPTOR | NEUROGEN CORPORATION (US) | 2002-02-14 | — | — | WO | claimed |
| WO-2002006213-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2002-01-24 | — | — | WO | claimed |
| EP-1150565-A1 | THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION bioscience AG (DE) | 2001-11-07 | — | — | EP | claimed |
| WO-2001044179-A1 | NOVEL SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | VERSICOR, INC. (US) | 2001-06-21 | — | — | WO | claimed |
| WO-2000045635-A1 | THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2000-08-10 | — | — | WO | claimed |
| US-5354495-A | Homo- or copolymerizable through ethylenic unsaturation | NIPPON PAINT CO., LTD. (JP) | 1994-10-11 | — | — | US | claimed |
| EP-0177122-B1 | ACRYLAMIDE DERIVATIVES | Nippon Paint Co., Ltd. (JP) | 1992-04-01 | — | — | EP | claimed |
| US-4935413-A | ELASTICITY, ADHESION AND DISPERSIBILITY | NIPPON PAINT CO., LTD. (JP) | 1990-06-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190092720-A1 | FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | HAVCR2, PHB2, PHB1 | CES2 596/4885CES1 234/4885PARP1 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.